PPH Legal Blog

GlaxoSmithKline, the manufacturer and distributor of Avandia, has come under fire for the multi-billion-dollar drug’s link to the development of PPH in those who have used Avandia for diabetes treatment. The scrutiny is coming with a price, and that was reinforced with a recent article in MarketWatch.com that told of GSK’s plans to shut […]

[Read more →]

Former FDA reviewer, Leo Lutwak, claims that once he began reviewing the drugs that make up Fen phen, he was concerned with the combination of these drugs.  Lutwak is also concerned about the way that the manufacturer, American Home Products, attempted to cover up damaging information about Fen phen.  They have the information and understand […]

[Read more →]

October 24, 2007: GlaxoSmithKline (GSK) unveiled a 1.5 billion pound restructuring plan that will include closing plants, outsourcing of manufacturing activities, and cutting an unspecified number of jobs. GSK made this announcement simultaneously with its report that third quarter profits had slid 7%, a dive the company claims is triggered by weaker sales of its […]

[Read more →]

Suffering from a disease that will affect you for the rest of your life is not something that any one wishes to go through.  Many people like to believe that developing such a disease is something that can not happen to them.  This is not the case, however.  Illness can affect anyone at any time.  […]

[Read more →]

Avandia is a drug manufactured by GlaxoSmithKline, and for a time it generated more than $2.2 billion per year in revenue. Eight percent of that revenue came from the Department of Veteran Affairs, which doled out Avandia to veterans at an enormous volume. The story appeared in the New York Times recently, and […]

[Read more →]